Skip to main content
Premium Trial:

Request an Annual Quote

Shield Diagnostics: David Esposito

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.